How many clinical trials are running for nerandomilast?

ClinicalTrials.gov lists more than 16 phase 2–4 nerandomilast trials. This page tracks the 16 largest by enrolment: 6 phase 2, 9 phase 3, and 1 phase 4 among them, with 9 actively recruiting. Updated daily.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare nerandomilast against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Respiratory · Live ClinicalTrials.gov data

Nerandomilast clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 nerandomilast trials on ClinicalTrials.gov by enrolment, 9 of them actively recruiting. The next phase 3 primary completion among them is expected Apr 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Apr 2027

Next phase 3 primary completion

6,923

Participants across trials

Boehringer Ingelheim

Lead sponsor by trial count

nerandomilast (16)14 active2022–2031

Hide completed

nerandomilast

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingNot yet recruitingCompleted

'22

'23

'24

'25

'26

'27

'28

'29

'30

'31

nerandomilast

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)P3

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)P3

CONQUESTP2

FIBRONEER™-ONP3

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)P2

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic DiseasesP3

MERCURION-IPFP3

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisP2

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisP3

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodP2

ARGiNAUTP2

NERAM-PFP4

This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingP2

VERANDA™-SScP3

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)P3

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionP3

Upcoming readouts

14 ahead · nerandomilast

Select a trial to load its full ClinicalTrials.gov record.

Key nerandomilast trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT07570888	NERAM-PF — This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety…	Phase 4	Not yet recruiting	Jun 2027
NCT06238622	FIBRONEER™-ON — A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Pa…	Phase 3	Recruiting	Apr 2027
NCT06806592	A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases	Phase 3	Recruiting	Jul 2027
NCT07299695	MERCURION-IPF — Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis	Phase 3	Recruiting	Jun 2028
NCT07201922	A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History o…	Phase 3	Recruiting	May 2029
NCT07540988	FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at …	Phase 3	Not yet recruiting	Dec 2028
NCT07366034	A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolesce…	Phase 3	Not yet recruiting	Apr 2029
NCT07497087	VERANDA™-SSc — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis	Phase 3	Not yet recruiting	Feb 2030
NCT05321069	A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IP…	Phase 3	Completed	Aug 2024
NCT05321082	A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitia…	Phase 3	Completed	Dec 2024
NCT06241560	A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1…	Phase 2	Recruiting	Aug 2026
NCT06195072	CONQUEST — Platform Clinical Study for Conquering Scleroderma	Phase 2	Recruiting	Nov 2026

tezepelumab (Tezspire)
Respiratory

Compare nerandomilast vs tezepelumab

FAQ

How many clinical trials are running for nerandomilast?: ClinicalTrials.gov lists more than 16 phase 2–4 nerandomilast trials. This page tracks the 16 largest by enrolment: 6 phase 2, 9 phase 3, and 1 phase 4 among them, with 9 actively recruiting. Updated daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare nerandomilast against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key nerandomilast trials

Related drug pipelines

FAQ

Be the first to access ComplyRx